Acute Exacerbations of COPD: Causes, Symptoms, Treatment & Prevention Guide (Chronic Bronchitis vs Emphysema)
Acute Exacerbations of Chronic Obstructive Pulmonary Disease
COPD can manifest as predominantly chronic bronchitis or predominantly emphysema.
There are many definitions of what represents an acute exacerbation of COPD. The most widely used definition evaluates the severity of exacerbation based on three symptoms: worsening dyspnea, increased sputum purulence, and increased sputum volume. Type 1 (severe) exacerbations include all three symptoms. Type 2 (moderate) exacerbations include two of the three symptoms. Type 3 (mild) exacerbations include one of these symptoms plus at least one of the following: upper respiratory tract infection within the past five days, fever without an apparent cause, increased wheezing, increased cough, or a 20% increase in respiratory rate or heart rate over baseline.
Acute exacerbations can be triggered by infections (viral or bacterial) or environmental exposures. However, many patients also have associated clinical conditions such as congestive heart failure or extrapulmonary infections. Determining whether symptoms are caused by COPD exacerbation or another medical condition is often a clinical challenge.
All patients presenting with symptoms consistent with acute exacerbation of COPD should undergo chest radiography to evaluate for pneumonia or pulmonary edema, and measurement of arterial oxygen concentration by arterial blood gas analysis. Routine spirometry has not been shown to be beneficial during acute exacerbations and is therefore not recommended; further evaluation should depend on the clinical scenario.
The medical management of acute exacerbations of COPD has been evaluated in many clinical trials. Treatment typically includes bronchodilator therapy, oxygen therapy, systemic corticosteroids, and antibiotics. Although the optimal duration of corticosteroid and antibiotic therapy has not been definitively established, studies consistently demonstrate benefits from these treatments.
Research on bronchodilator therapy shows that inhaled bronchodilators are superior to systemic bronchodilators. There is no clear advantage of nebulization therapy compared with treatment delivered through a metered-dose inhaler.
Initial Evaluation and Medical Management:
Initial evaluation of a patient with suspected acute exacerbation of COPD begins with a complete clinical assessment that includes medical history and physical examination. Basic laboratory investigations should be performed, including a complete blood count and a basic metabolic panel. A chest radiograph should be obtained to evaluate for alternative or additional diagnoses such as pneumonia. Arterial blood gas analysis should also be performed to assess oxygenation and ventilation.
After this evaluation, clinicians determine whether the patient’s symptoms are consistent with a COPD exacerbation. If the symptoms are not consistent with COPD exacerbation, the underlying medical condition responsible for the symptoms should be treated.
If the evaluation confirms an acute exacerbation of COPD, treatment should be initiated. Oxygen therapy should be administered through a nasal cannula or face mask, with the goal of maintaining a partial pressure of oxygen (PaO₂) above 60 mm Hg or oxygen saturation above 90%. Care must be taken not to overcorrect hypoxemia, as excessive oxygen administration may lead to hypercapnia.
Bronchodilator therapy should be started, usually with short-acting β₂-adrenergic receptor agonists and short-acting anticholinergic agents. Anticholinergic agents often have a more favorable side-effect profile and are commonly used as first-line therapy. If symptoms persist despite maximum anticholinergic therapy, a short-acting β₂-agonist can be added.
Systemic corticosteroid therapy should also be administered because it has been shown to improve outcomes in patients with acute exacerbations of COPD. In addition, antibiotic therapy should be considered, particularly when bacterial infection is suspected. If the patient’s respiratory condition worsens or fails to improve, mechanical ventilatory support may be required.
Oxygen and Corticosteroid Therapy
Although oxygen therapy has not been studied as extensively as other treatments, it is widely accepted as beneficial in acute exacerbations. Oxygen should be administered by nasal cannula or face mask to achieve a PaO₂ greater than 60 mm Hg or oxygen saturation between 90% and 92%, while avoiding excessive oxygen administration that could precipitate hypercapnia.
Corticosteroid therapy has been extensively studied and clearly benefits patients with acute exacerbations of COPD. Studies comparing short courses with longer courses of corticosteroid therapy suggest that shorter treatment durations may be sufficient in many patients.
Antibiotic Therapy
Antibiotics are frequently used in the treatment of COPD exacerbations because bacterial infections commonly contribute to these episodes. Evidence indicates that antibiotic therapy can improve clinical outcomes, especially in patients with increased sputum purulence, sputum volume, and dyspnea.
Common pathogens include Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis. Various antibiotics have been studied, including amoxicillin, trimethoprim-sulfamethoxazole, doxycycline, macrolides, and fluoroquinolones. The choice of antibiotic should consider local resistance patterns and the severity of illness.
Mechanical Ventilation in COPD Exacerbation:
Mechanical ventilatory support is an important treatment option in patients with severe acute exacerbations of COPD who develop respiratory failure. Noninvasive positive-pressure ventilation (such as BiPAP) is often beneficial and may reduce the need for endotracheal intubation.
If the patient cannot tolerate noninvasive ventilation, or if there are contraindications such as cardiac or respiratory arrest, severe agitation, inability to protect the airway, excessive secretions, or anatomical abnormalities preventing mask fitting, invasive mechanical ventilation with endotracheal intubation should be performed.
Patients receiving mechanical ventilation should have ventilator settings adjusted to accommodate the physiology of COPD. Typical initial settings include assist-control mode with a respiratory rate of 10–12 breaths per minute, tidal volume around 8 mL/kg, and positive end-expiratory pressure (PEEP) of 0–5 cm H₂O. High inspiratory flow rates may be used to allow sufficient time for exhalation and reduce air trapping.
These patients should not necessarily be ventilated to achieve a completely normal arterial blood gas level; instead, permissive hypercapnia close to the patient’s baseline may be acceptable.
Clinicians must monitor for the development of auto-PEEP, which can occur with inadequate expiratory time, excessive tidal volumes, or high respiratory rates. Auto-PEEP may reduce venous return and cause hypotension. Applying external PEEP can sometimes offset this effect and help patients trigger the ventilator more effectively.
Patients on mechanical ventilation should receive prophylaxis for deep venous thrombosis and stress ulcers. Nutritional support is also important but should avoid excessive carbohydrate intake because this can increase carbon dioxide production.